The New England Journal of Medicine Publishes First Data to Demonstrate the Potential for Disease Modification in Dravet Syndrome
NervGen Pharma Appoints Shamim Ruff as Chief Regulatory Affairs Officer and Christine McSherry as SVP, Patient Advocacy and Clinical Affairs [Yahoo! Finance]
Stoke Therapeutics (STOK) was upgraded by Wolfe Research to "strong-buy".
Stoke Therapeutics to Present at the TD Cowen 46th Annual Health Care Conference
Stoke Therapeutics (NASDAQ:STOK) is now covered by analysts at Wolfe Research. They set an "outperform" rating on the stock.